Welcome to our dedicated page for NEKTAR THERAPEUTICS SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics (NKTR) notice reports a proposed sale of 6,666 common shares with an aggregate market value of $256,837.92, representing a portion of ~19.02 million shares outstanding. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the approximate date of sale as 09/05/2025 on NASDAQ. The 6,666 shares to be sold were acquired through restricted stock vesting between 05/15/2017 and 05/15/2021 as compensation from the issuer, and the acquisition table shows the same 6,666-share total when summed. The filer also disclosed three sales in the prior three months totaling 8,239 shares for gross proceeds of $261,188.89. The notice includes the seller's attestation regarding absence of undisclosed material adverse information.
Nektar Therapeutics (NKTR) insider sale disclosed on Form 4. Jonathan Zalevsky, Chief R&D Officer, reported selling 485 shares of common stock on 09/02/2025 under a Rule 10b5-1 trading plan at a weighted average price of $30.10 per share. After the sale he beneficially owned 19,183 shares, held directly. The filing states the trades executed at prices ranging from $30.00 to $30.28 and the Form 4 was signed by an attorney-in-fact on 09/04/2025.
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), reported an insider sale on 09/02/2025. The filing shows a disposition of 1,500 shares of common stock executed at a weighted-average price of $30.16, reducing his direct beneficial ownership to 67,840 shares. The report notes the sale was made pursuant to a Rule 10b5-1 trading plan and that the trades occurred at prices between $30.00 and $30.30. The form also discloses an indirect ownership of 28 shares held by his spouse. The filing was signed by an attorney-in-fact on 09/04/2025.
Nektar Therapeutics (NKTR) filing reports a proposed sale of 5,166 common shares through Fidelity Brokerage Services with an aggregate market value of $174,119.16, to be sold approximately on 09/04/2025 on NASDAQ. The filing details that these shares were acquired via restricted stock vesting between 11/15/2017 and 05/15/2019, totaling specified lots (190; 1,346; 1,073; 1,072; 1,011; 474). It also discloses recent sales by the same person: 1,573 shares on 08/19/2025 for $41,826.23 and 1,500 shares on 09/02/2025 for $45,243.50. The signer represents no undisclosed material adverse information.
Nektar Therapeutics (NKTR) filed a Form 144 notice for a proposed sale of 1,721 common shares held by Jonathan Zalevsky. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an aggregate market value reported as $57,688.44 and the company outstanding share count shown as 19,018,573. The approximate sale date is 09/04/2025. The shares were acquired via restricted stock vesting on four dates in 2023–2024 (totaling 1,721 shares). The filing also discloses two prior sales in the past three months: 725 shares on 08/19/2025 for $19,277.83 and 485 shares on 09/02/2025 for $14,600.10. The filer attests there is no undisclosed material information.
Nektar Therapeutics (NKTR) Form 144 notice for proposed sale of securities. An insider intends to sell 485 shares of common stock via Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $14,600.10 and an approximate sale date of 09/02/2025. The shares were acquired by restricted stock vesting on 11/15/2023 and were issued as compensation. The form also discloses a recent sale by the same person of 725 shares on 08/19/2025 for gross proceeds of $19,277.83. The filer certifies no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.
Nektar Therapeutics (NKTR) submitted a Form 144 notifying intent to sell 1,500 common shares through Fidelity Brokerage Services (900 Salem Street, Smithfield RI) with an aggregate market value of $45,243.50. The filing reports approximately 19,018,573 shares outstanding and an approximate sale date of 09/02/2025 on the NASDAQ. The shares were originally acquired as restricted stock vesting on 02/15/2018 (655 shares) and 05/15/2018 (845 shares) with payment characterized as compensation. The filing also discloses a prior sale by Howard Robin of 1,573 shares on 08/19/2025 for gross proceeds of $41,826.23. The notice includes the standard Rule 144 representation regarding absence of undisclosed material information.
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported transactions on 08/19/2025. He sold 725 shares to cover tax withholding from RSU vesting at a weighted average price of $26.59 (trades ranged $26.19–$27.15). After that sale he beneficially owned 19,668 shares. The filing also reports an acquisition/vesting event for 16,666 stock options (exercise price $0.50) recorded as acquired on 08/19/2025; those options correspond to 16,666 underlying common shares and are shown as directly beneficially owned following the transaction. The filing notes a one-for-fifteen reverse stock split effective 06/08/2025 and explains the option grant and vesting timing from the 12/13/2023 award.
Mark A. Wilson, Chief Legal Officer of Nektar Therapeutics (NKTR), reported insider transactions dated 08/19/2025. On that date he sold 676 shares of common stock at a weighted-average price of $26.59 to cover tax withholding arising from the vesting of restricted stock units; the sale was executed in multiple trades at prices ranging $26.19 to $27.15. Following the reported sale, he beneficially owned 20,312 shares (which includes 508 shares held in the company ESPP). The filing also reports that 21,666 stock options (exercise price $0.50) became vested/was acquired on 08/19/2025; these options relate to a grant made 12/13/2023 and were subject to performance and time-based vesting, with the performance condition satisfied 07/17/2025. All share amounts have been adjusted for a one-for-fifteen reverse stock split effective 06/08/2025.
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), reported insider activity. He sold 1,573 shares of common stock to cover tax withholding at a weighted-average price of $26.59, leaving 69,340 shares beneficially owned directly and 28 shares indirectly by his spouse (amounts adjusted for a one-for-fifteen reverse stock split).
Mr. Howard also had 86,666 stock options exercised that became vested after the Organization and Compensation Committee determined the performance-based vesting condition was satisfied; these options have a $0.50 exercise price and underlying 86,666 shares with an expiration of December 12, 2031.